Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098892011> ?p ?o ?g. }
- W2098892011 endingPage "4211" @default.
- W2098892011 startingPage "4200" @default.
- W2098892011 abstract "A series of 3-aryl-1,6-naphthyridine-2,7-diamines and related 2-ureas were prepared and evaluated as inhibitors of the FGF receptor-1 tyrosine kinase. Condensation of 4,6-diaminonicotinaldehyde and substituted phenylacetonitriles gave intermediate naphthyridine-2,7-diamines, and direct reaction of the monoanion of these (NaH/DMF) with alkyl or aryl isocyanates selectively gave the 2-ureas in varying yields (23-93%). For the preparation of more soluble 7-alkylamino-2-ureas, a number of protecting groups for the 2-amine were evaluated (phthaloyl, 4-methoxybenzyl) following selective blocking of the 7-amine (trityl), but these were not superior to the (required) 2-tert-Bu-urea group itself. Direct alkylation of the anion of the (unprotected) 7-amino group with excess 4-(3-chloropropyl)morpholine in DMF gave low (10%) yields of the desired product, but alkylation of the 7-acetamido anion, followed by mild alkaline hydrolysis, raised this to 64%. 3-Phenyl analogues were nonspecific inhibitors of isolated c-Src, FGFR, and PDGFR tyrosine kinases, whereas 3-(2,6-dichlorophenyl) analogues were most effective against c-Src and FGFR, and 3-(3,5-dimethoxyphenyl) derivatives showed high selectivity for FGFR alone. A water-soluble (7-morpholinylpropylamino) analogue retained high FGFR potency (IC(50) 31 nM) and selectivity. Pairwise comparison of the 1, 6-naphthyridines and the corresponding known pyrido[2,3-d]pyrimidine analogues showed little differences in potency or patterns of selectivity, suggesting that the 1-aza atom of the latter is not important for activity. A 7-acetamide derivative inhibited the growth of FGFR-expressing tumor cell lines and was particularly potent against HUVECs (IC(50) 4 nM). This compound was also a very potent inhibitor of HUVEC microcapillary formation (IC(50) 0.01 nM) and Matrigel invasion (IC(50) 7 nM) and showed significant in vivo antitumor effects in a highly vascularized mammary adenocarcinoma 16/c model at nontoxic doses. The compounds are worthy of further evaluation as antiangiogenesis agents." @default.
- W2098892011 created "2016-06-24" @default.
- W2098892011 creator A5004978747 @default.
- W2098892011 creator A5008862326 @default.
- W2098892011 creator A5009824509 @default.
- W2098892011 creator A5011084818 @default.
- W2098892011 creator A5023901201 @default.
- W2098892011 creator A5029175020 @default.
- W2098892011 creator A5032757693 @default.
- W2098892011 creator A5040343725 @default.
- W2098892011 creator A5040350348 @default.
- W2098892011 creator A5041403992 @default.
- W2098892011 creator A5052349311 @default.
- W2098892011 creator A5058847361 @default.
- W2098892011 creator A5065494091 @default.
- W2098892011 creator A5080646218 @default.
- W2098892011 creator A5081986848 @default.
- W2098892011 creator A5082013627 @default.
- W2098892011 creator A5091672542 @default.
- W2098892011 date "2000-10-10" @default.
- W2098892011 modified "2023-10-06" @default.
- W2098892011 title "3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine Kinase" @default.
- W2098892011 cites W1491520169 @default.
- W2098892011 cites W1987873158 @default.
- W2098892011 cites W1989070651 @default.
- W2098892011 cites W1992388470 @default.
- W2098892011 cites W2007037871 @default.
- W2098892011 cites W2015786768 @default.
- W2098892011 cites W2079054349 @default.
- W2098892011 cites W2079870631 @default.
- W2098892011 cites W2080071221 @default.
- W2098892011 cites W2084467563 @default.
- W2098892011 cites W2092305222 @default.
- W2098892011 cites W2096950509 @default.
- W2098892011 cites W2133160109 @default.
- W2098892011 cites W2158743409 @default.
- W2098892011 cites W2315424109 @default.
- W2098892011 cites W2321996036 @default.
- W2098892011 cites W2327417298 @default.
- W2098892011 cites W2328771712 @default.
- W2098892011 doi "https://doi.org/10.1021/jm000161d" @default.
- W2098892011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11063616" @default.
- W2098892011 hasPublicationYear "2000" @default.
- W2098892011 type Work @default.
- W2098892011 sameAs 2098892011 @default.
- W2098892011 citedByCount "38" @default.
- W2098892011 countsByYear W20988920112012 @default.
- W2098892011 countsByYear W20988920112013 @default.
- W2098892011 countsByYear W20988920112014 @default.
- W2098892011 countsByYear W20988920112015 @default.
- W2098892011 countsByYear W20988920112016 @default.
- W2098892011 countsByYear W20988920112018 @default.
- W2098892011 countsByYear W20988920112019 @default.
- W2098892011 countsByYear W20988920112020 @default.
- W2098892011 countsByYear W20988920112021 @default.
- W2098892011 countsByYear W20988920112022 @default.
- W2098892011 countsByYear W20988920112023 @default.
- W2098892011 crossrefType "journal-article" @default.
- W2098892011 hasAuthorship W2098892011A5004978747 @default.
- W2098892011 hasAuthorship W2098892011A5008862326 @default.
- W2098892011 hasAuthorship W2098892011A5009824509 @default.
- W2098892011 hasAuthorship W2098892011A5011084818 @default.
- W2098892011 hasAuthorship W2098892011A5023901201 @default.
- W2098892011 hasAuthorship W2098892011A5029175020 @default.
- W2098892011 hasAuthorship W2098892011A5032757693 @default.
- W2098892011 hasAuthorship W2098892011A5040343725 @default.
- W2098892011 hasAuthorship W2098892011A5040350348 @default.
- W2098892011 hasAuthorship W2098892011A5041403992 @default.
- W2098892011 hasAuthorship W2098892011A5052349311 @default.
- W2098892011 hasAuthorship W2098892011A5058847361 @default.
- W2098892011 hasAuthorship W2098892011A5065494091 @default.
- W2098892011 hasAuthorship W2098892011A5080646218 @default.
- W2098892011 hasAuthorship W2098892011A5081986848 @default.
- W2098892011 hasAuthorship W2098892011A5082013627 @default.
- W2098892011 hasAuthorship W2098892011A5091672542 @default.
- W2098892011 hasConcept C118792377 @default.
- W2098892011 hasConcept C131779359 @default.
- W2098892011 hasConcept C155647269 @default.
- W2098892011 hasConcept C161790260 @default.
- W2098892011 hasConcept C164361826 @default.
- W2098892011 hasConcept C170493617 @default.
- W2098892011 hasConcept C178790620 @default.
- W2098892011 hasConcept C185592680 @default.
- W2098892011 hasConcept C2780263894 @default.
- W2098892011 hasConcept C2780365088 @default.
- W2098892011 hasConcept C2781056017 @default.
- W2098892011 hasConcept C2781076698 @default.
- W2098892011 hasConcept C42362537 @default.
- W2098892011 hasConcept C55493867 @default.
- W2098892011 hasConcept C71240020 @default.
- W2098892011 hasConceptScore W2098892011C118792377 @default.
- W2098892011 hasConceptScore W2098892011C131779359 @default.
- W2098892011 hasConceptScore W2098892011C155647269 @default.
- W2098892011 hasConceptScore W2098892011C161790260 @default.
- W2098892011 hasConceptScore W2098892011C164361826 @default.
- W2098892011 hasConceptScore W2098892011C170493617 @default.
- W2098892011 hasConceptScore W2098892011C178790620 @default.
- W2098892011 hasConceptScore W2098892011C185592680 @default.